Do not double doses.Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Spoke w/ Kim - Stopped Metformin due to side effects - took 1 dose today Read More venlafaxine hydrochloride (Effexor) = Extreme agitation and racing thoughts. Ask your pharmacist how to dispose of medicines no longer required. as brand; see generic] infections, bacterial [3 mo]
Individual plans may vary 2002
This website also contains material copyrighted by 3rd parties. Remission induction of active, mild-to-moderate diseaseLialda: 2.4-4.8 g PO qDay with meal for up to 8 weeksCardiac disorders: Pericarditis, pericardial effusion, myocarditisGastrointestinal: Pancreatitis, cholecystitis, gastritis, gastroenteritis, gastrointestinal bleeding, perforated peptic ulcerHepatic: Jaundice, cholestatic jaundice, hepatitis, liver necrosis, liver failure, Kawasaki-like syndrome including changes in liver enzymesImmune system disorders: Anaphylactic reaction, Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), angioedemaMusculoskeletal and connective tissue disorders: MyalgiaNeurological/psychiatric: Peripheral neuropathy, Guillain-Barre syndrome, transverse myelitis, intracranial hypertensionRenal disorders: Interstitial nephritis, renal failure, minimal change nephropathy, nephrogenic diabetes insipidusRespiratory, thoracic and mediastinal disorders: Hypersensitivity pneumonitis (including interstitial pneumonitis, allergic alveolitis, eosinophilic pneumonitis)Skin: Psoriasis, pyoderma gangrenosum, erythema nodosum, photosensitivityRectal suspension: Hypersensitivity to salicylates, aminosalicylates or to any ingredients in the suppository vehicleSulfasalazine hypersensitivity, renal insufficiency, coagulation abnormalities, pyloric stenosisDo not use with lactulose or drugs that lower intestinal pHAlthough pericarditis rarely occurs, investigate any chest pain or dyspneaHepatic failure may occur, particularly with preexisting liver impairmentMay lead to falsely elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection, because of the similarity in the chromatograms of normetanephrine and mesalamine’s main metabolite, N-acetyl aminosalicylic acid; an alternative, selective assay for normetanephrine should be consideredWorsening of colitis/IBD may occur following initiation of therapyRenal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and renal failure, reported; evaluate renal function prior to initiation of therapy and periodically while on therapyEvaluate the risks and benefits in patients with known renal impairment or taking nephrotoxic drugs; monitor renal functionAcute intolerance syndrome may occur; symptoms may be difficult to distinguish from an ulcerative colitis exacerbation; monitor for worsening symptoms; discontinue if acute intolerance syndrome suspectedHypersensitivity reactions, including myocarditis and pericarditis reported; evaluate patients immediately and discontinue if hypersensitivity reaction suspectedEvaluate the risks and benefits in patients with known liver impairmentPyloric stenosis or other organic or functional obstruction in upper gastrointestinal tract may cause prolonged gastric retention of drug, which would delay mesalamine release in colon; avoid drug in patients at risk of upper gastrointestinal tract obstructionPatients with pre-existing skin conditions such as atopic dermatitis and atopic eczema have reported more severe photosensitivity reactions; advise patients to avoid sun exposure, wear protective clothing, and use a broad-spectrum sunscreen when outdoorsPhenylalanine can be harmful to patients with phenylketonuria (PKU); product contains phenylalanine, a component of aspartame; each 0.375 g capsule contains 0.56 mg of phenylalanine; before prescribing to a patient with PKU, consider combined daily amount of phenylalanine from all sources including this drugPregnancy: Limited published data on mesalamine use in pregnant women are insufficient to inform a drug-associated risk; no evidence of teratogenicity was observed in rats or rabbits when treated during gestation with orally administered mesalamine at doses greater than the recommended human intra-rectal doseLactation: Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on the breastfed child from therapy or from underlying maternal conditions; mesalamine and its N-acetyl metabolite are present in human milk in undetectable to small amounts; there are limited reports of diarrhea in breastfed infants; there is no information on effects of drug on milk production; monitor breastfed infants for diarrheaA: Generally acceptable.
2002 Asacol 400mg MR tablets should NOT be taken with Women who are pregnant or breast-feeding should not take Asacol 400mg MR tablets unless advised otherwise by their doctor.Ask your doctor or pharmacist for advice before taking any medicine.Before you start treatment with Asacol 400mg tablets you will have a blood and urine test to check how well your kidneys are working and what your blood is doing.